PRONAR: Organ Preservation in Locally Advanced Rectal Cancer
Study Details
Study Description
Brief Summary
PRONAR trial aims to assess if treatment with organ preservation in stage II and III rectal cancer after a complete or almost complete response to neoadjuvant treatment is feasible and safe in our environment.
The main objective of this project is to implement the organ preservation strategy in the treatment of rectal cancer in our environment within a clinical study that allows the analysis of its results in terms of survival.
The secondary objective is to assess local relapse, distant relapse and quality of life.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
After pathology confirmed rectal cancer patients with stage II and III (MRI, CT and endoscopy) will be identified in the first visit to Medical Oncology Department. Patients will receive the most appropriate neoadjuvant treatment according to clinical guidelines.
Response to neoadjuvant treatment will be assessed by MRI. Those patients with a complete response in MRI, confirmed by endoscopy, will be offered a "watch and wait" strategy. Patients with a complete response in MRI, with an almost complete response in endoscopy, will be offered transanal endoscopic microsurgery. All patients with complete or near complete response will sign an informed consent before study entry.
Radical surgery will be performed in patients without complete or almost complete response criteria after neoadjuvant treatment.
Patients in organ preserving strategy will be subjected to a more intensive follow up schedule, including MRI and endoscopy, compared to patients with radical surgery.
As the complete histopathologic response rate after neoadjuvant treatment in locally advanced rectal cancer is approximately 15-20%, considering that approximately 40 patients with locally advanced rectal cancer are diagnosed annually in our setting, approximately 6-8 patients per year could be potentially recruited for this project, until reaching an initial sample of 30 patients for evaluation.
The following results will be analyzed:
-
Percentage of complete and almost complete responses.
-
Percentage of watch and wait and transanal endoscopic microsurgery.
-
Disease free survival.
-
Overall survival.
-
Local relapse rate.
-
Distant relapse rate.
-
Treatment and outcomes of relapses.
-
Colostomy free survival.
-
Quality of life.
All data will be obtained from patient's medical records
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Organ Preservation The experimental strategy is the omission of radical surgery if complete or almost complete response after neoadjuvant treatment for locally advanced rectal cancer |
Other: Organ Preservation
Patients with a complete response or a almost complete response after neoadjuvant treatment will be offered an organ preservation strategy
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Percentage of organ preservative strategies after neoadjuvant treatment in locally advanced rectal cancer [5 years]
Patients with a complete or almost complete response after a neoadjuvant treatment will be offered an organ preservation strategy
Secondary Outcome Measures
- Local relapse rate [2 years and 5 years]
Occurrence of local relapse in patients with an organ preservation strategy
- Distant relapse rate [2 years and 5 years]
Occurrence of distant relapse in patients with an organ preservation strategy
- Quality of Life in oncological patients [3 months; 1 year and annually until 5 years]
Assess QLQ-C30 in patients with an organ preservation strategy
- Quality of Life in patient with rectal cancer [3 months, 1 year and annually until 5 years]
Assess QLQ-CR38 in patients with an organ preservation strategy
Other Outcome Measures
- Percentage of complete and almost complete responses [8 weeks after neoadjuvant treatment]
Occurrence of complete and almost complete responses assessed by MRI and confirmed by endoscopy after neoadjuvant treatment
- Disease free survival [2 years and 5 years]
Time without recidive
- Overall Survival [2 years and 5 years]
Survival time from surgery
- Treatment of relapses [2 years and 5 years]
Treatment administered in case of relapse
- Outcome of relapses [2 years and 5 years]
Survival after a relapse
- Colostomy free survival [2 years and 5 years]
Time without colostomy
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients with confirmed histopathological diagnosis of rectal adenocarcinoma.
-
Patients treated with neoadjuvant chemoradiotherapy or neoadjuvant radiotherapy associated or not with induction chemotherapy.
-
Patients with evidence of complete or near complete response criteria after completion of neoadjuvant treatment (approximately 8 weeks later). Response criteria should be based on digital rectal examination, flexible rectoscopy and MRI.
Exclusion Criteria:
- Evidence of distant metastases.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Hospital General Universitario de Elche | Elche | Alicante | Spain | 03203 |
Sponsors and Collaborators
- Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana
- Hospital General Universitario Elche
Investigators
- Principal Investigator: Javier Gallego, PhD, Hospital General Universitario de Elche
- Study Director: Javier Gallego, PhD, Hospital General Universitario de Elche
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- PRONAR V1.0: 19DEC2016